CELLVANTAGE
LIVE

Serial Number

99563920

Owner

Virica Biotech Inc.

Attorney

Nicole K. McLaughlin

Filing Date

Dec 23, 2025

Add to watchlist:

No watchlists yet
View on USPTO

CELLVANTAGE Trademark

Serial Number: 99563920

CELLVANTAGE is a trademark filed by Virica Biotech Inc. on December 23, 2025. The trademark is classified under Class 1 (Chemicals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Virica Biotech Inc. (3 trademarks)

7 Bayview Station Road
Ottawa, Ontario K1Y2C5 , CA

Entity Type: 03

Trademark Details

Filing Date

December 23, 2025

Registration Date

Not Registered

Goods & Services

Biological production, namely, custom manufacture of biological preparations in the field of gene therapy and cell therapies; biological production, namely, custom manufacture of biological preparations in the field of vaccines

Scientific research and analysis for scientific research purposes in the field of gene and cell therapies; scientific research and analysis for scientific research purposes in the field of vaccines, process development and evaluation; research and development in the field of vaccines; testing services in the field of vaccines; laboratory research in the field of gene expression; research in the field of gene therapy; research and development in the medical biotechnology field; development of biotechnology; research and development in the pharmaceutical and biotechnology fields

Cell culture reagents for laboratory use, namely, for research use; cell culture reagents for scientific and research purposes; antibody reagents for scientific purposes; diagnostic reagents for medical-scientific research use; chemical preparations for the use in the production of medicines; chemical preparations for use in the manufacture of pharmaceuticals; chemical preparations for scientific purposes; biochemical preparations for scientific purposes; catalysts in the nature of small molecules for use in increasing viral yield for use in the manufacture of vaccines and viral medicines; chemical and biochemical preparations for scientific use, research use, and laboratory research use; chemical and biochemical preparations for scientific use and for scientific research use; reagents for scientific and research use, in the field of genetics, for the transfer of biological molecules into living cells, integration of foreign nucleic acids into the genome of living cells and production of transfected cells, cell lines, recombinant proteins, peptides, antibodies, viruses, and pseudo-viral particles; chemical and biochemical preparations, agents, and reagents sold as a unit for producing viruses using transfection for scientific use and for scientific research use

Filing History

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Aug 18, 2026 GNS3
LETTER OF SUSPENSION E-MAILED
Aug 18, 2026 GNSL
SUSPENSION LETTER WRITTEN
Aug 18, 2026 CNSL
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 18, 2026 GNEN
EXAMINER'S AMENDMENT ENTERED
Aug 18, 2026 XAEC
EXAMINERS AMENDMENT E-MAILED
Aug 18, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 18, 2026 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 30, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 30, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 30, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 30, 2026 GNRN
NON-FINAL ACTION E-MAILED
Apr 30, 2026 GNRT
NON-FINAL ACTION WRITTEN
Apr 30, 2026 CNRT
ASSIGNED TO EXAMINER
Apr 27, 2026 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 15, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Dec 23, 2025 MAFR
NEW APPLICATION ENTERED
Dec 23, 2025 NWAP